Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03960177 · ClinicalTrials.gov registry record · Early Phase 1
Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
A Early Phase 1 study of Osteosarcoma, sponsored by OHSU Knight Cancer Institute.
- Active
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT03960177: Active Early Phase 1 study of Osteosarcoma, sponsored by OHSU Knight Cancer Institute.
NCT03960177 is a Early Phase 1 study of Osteosarcoma that is active but no longer recruiting, run by OHSU Knight Cancer Institute. The registered enrollment target is 12 participants, below the 302-participant average among 46 other Osteosarcoma trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03960177, a Early Phase 1 study of Osteosarcoma, is active but no longer recruiting, sponsored by OHSU Knight Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This early phase I trial studies how well glucarpidase works in reducing toxicity in patients with osteosarcoma receiving high dose methotrexate treatment. Glucarpidase may reduce the levels of methotrexate in patients' blood and lead to shorter hospitalizations and a reduction in toxicities.
Primary Outcome
Will be estimated with an exact 95% confidence interval (CI).
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Glucarpidase
Study Locations (3)
Florida
- Mayo Clinic in Florida - Jacksonville
Oregon
- OHSU Knight Cancer Institute - Portland
Pennsylvania
- University of Pennsylvania/Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-03-27 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
What the registry record for NCT03960177 still lists
NCT03960177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 302-participant average among 46 other Osteosarcoma trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03960177 reports a single indexed study location in Florida, Oregon, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03960177 about?
NCT03960177 is a clinical study titled "Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma". This early phase I trial studies how well glucarpidase works in reducing toxicity in patients with osteosarcoma receiving high dose methotrexate treatment. Glucarpidase may reduce the levels of methotrexate in patients' blood and lead to shorter hospitalizations and a reduction in toxicities.
What is the current status of trial NCT03960177?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2019-03-27. Estimated completion is 2026-12-31.
What conditions does trial NCT03960177 study?
This clinical trial studies the following conditions: Osteosarcoma.
What interventions are being tested in trial NCT03960177?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Glucarpidase (DRUG).
Who is sponsoring clinical trial NCT03960177?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03960177 being conducted?
This trial has 3 study locations across Florida, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03960177's enrollment target sits among peer trials
12 42nd of 46 higher than 4 of 46 other Osteosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Losartan + Sunitinib in Treatment of Osteosarcoma
RECRUITING · Phase 1
-
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
RECRUITING · Phase 3
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI